HC Wainwright, Citigroup, Goldman Sachs, and Jefferies Financial Group maintain "buy" ratings for ArriVent BioPharma, with target prices ranging from $27 to $35.

HC Wainwright reaffirms "buy" rating for ArriVent BioPharma (NASDAQ: AVBP), target price $25, implying 34.77% upside. Citigroup, Goldman Sachs, and Jefferies Financial Group also give "buy" ratings with target prices ranging from $27 to $35. ArriVent BioPharma, a clinical-stage biopharma, develops cancer therapies. Institutional investors own 9.48% of the stock.